Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1082 of 6351
-
New drug cocktail shows promise for Tough-to-Treat endometrial cancer
Disease control OngoingThis phase II trial studies how well everolimus and letrozole with or without ribociclib work in treating participants with endometrial cancer that has spread to other areas of the body or has come back. Ribociclib may stop the growth of tumor cells by blocking some of the enzyme…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Can a phosphate binder curb kidney stone risk?
Disease control CompletedThis study investigates the efficacy and the safety of Lanthanum Carbonate for the reduction of urinary oxalate excretion in patients with secondary hyperoxaluria and nephrolithiasis.
Phase 3 • Sponsor: Universitair Ziekenhuis Brussel • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New cocktail aims to crush High-Risk myeloma
Disease control OngoingA Clinical Phase II, multicenter, Open-label study evaluating iNduction, consolidation and maintenance treatment with Isatuximab (SAR650984), Carfilzomib, LEnalidomide and Dexamethasone (I-KRd) in Primary diagnosed high-risk multiple myeloma paTients
Phase 2 • Sponsor: Universitätsklinikum Hamburg-Eppendorf • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New hope for rare sarcoma patients: AL3818 drug trial underway
Disease control Recruiting nowTHIS STUDY IS CURRENTLY RECRUITING PATIENTS WITH ALVEOLAR SOFT PART SARCOMA ONLY AND IS NO LONGER RECRUITING PATIENTS WITH SYNOVIAL SARCOMA OR LEIOMYOSARCOMA. This study evaluates the safety and efficacy of AL3818 (anlotinib) hydrochloride in the treatment of metastatic or advan…
Phase 3 • Sponsor: Advenchen Laboratories, LLC • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Can adding radiation boost immunotherapy against tough cancers?
Disease control OngoingThis randomized phase II trial studies the side effects of durvalumab and tremelimumab and to see how well they work with or without high or low-dose radiation therapy in treating patients with colorectal or non-small cell lung cancer that has spread to other parts of the body (m…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Electric pulses plus immunotherapy take on tough pancreatic cancer
Disease control Recruiting nowCompare the efficacy and tolerability of irreversible electroporation in combination with Nivolumab in patients with locally advanced pancreatic cancer.
Phase 2 • Sponsor: University of Louisville • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New mRNA vaccine shows promise in fighting solid tumors
Disease control OngoingThe purpose of this study is to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone and in combination in participants with solid tumors.
Phase 1 • Sponsor: ModernaTX, Inc. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug combo shows promise for tough prostate cancer
Disease control OngoingThis randomized phase II trial studies how well olaparib with or without cediranib works in treating patients with castration-resistant prostate cancer that has spread to other places in the body (metastatic). PARPs are proteins that help repair DNA mutations. PARP inhibitors, su…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New drug cocktail takes on rare, aggressive breast cancer
Disease control OngoingThis phase II trial studies how well atezolizumab, cobimetinib, and eribulin work in treating patients with inflammatory breast cancer that has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's imm…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Can biomarkers guide MS treatment? new trial aims to find out
Disease control Recruiting nowBackground: In people with multiple sclerosis (MS), brain and cerebrospinal fluid (CSF) biomarkers indicate inflammation or disease. Researchers want to see if 4 drugs given alone or combined affect MS biomarkers. They want to see if a change in biomarker levels can predict whic…
Phase 1/2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New drug cocktail aims to tackle tough blood cancers
Disease control Recruiting nowThis phase II trial studies the side effects and how well combination chemotherapy works in treating patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, Burkitt lymphoma/leukemia, or double-hit lymphoma/leukemia that has come back or does not respond to treatment.…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New transplant method aims to reduce dangerous immune reactions
Disease control OngoingThis phase Ib/2 trial studies how well chemotherapy, total body irradiation, and post-transplant cyclophosphamide work in reducing rates of graft versus host disease in patients with hematologic malignancies undergoing a donor stem cell transplant. Drugs used in the chemotherapy,…
Phase 1/2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Can targeted exercises ease mild pelvic organ prolapse without surgery?
Disease control CompletedOBJECTIVE: To evaluate the effectiveness of an individualized pelvic floor physiotherapy programme combined with lifestyle education compared with lifestyle education alone in women with stage I or II pelvic organ prolapse (POP). DESIGN: Randomized controlled clinical trial with…
Sponsor: University of Alcala • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Spinal implant sparks hope for leg movement in paralyzed patients
Disease control Recruiting nowThis study will evaluate a method to optimize parameter settings in epidural spinal cord stimulation used to recover lower extremity volitional movement. The study will also characterize improvement in autonomic function (such as blood pressure control) and other functions relate…
Sponsor: University of Minnesota • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Chilling the spine: could hypothermia heal paralysis?
Disease control Recruiting nowThis study is a prospective multi-center trial designed to determine the safety profile and efficacy of modest (33ºC) intravascular hypothermia following acute cervical (C1 to C8) Spinal Cord Injury (SCI).
Sponsor: University of Miami • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New infusion strategy aims to keep CAR t cells fighting leukemia longer
Disease control OngoingPatients with relapsed or refractory CD 19+ leukemia who have achieved remission after CD19 CAR-T cell treatment sometimes relapse because the CD 19 CAR-T cells decrease in number over time. Study PLAT-03 will test whether administering T cell antigen presenting cells (T-APCs) at…
Phase 1 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Can a Triple-Drug combo outsmart Immunotherapy-Resistant lung cancer?
Disease control OngoingThe purpose of this study is to test the safety of a combination of three drugs, pembrolizumab, guadecitabine and mocetinostat. Pembrolizumab is a drug given by vein and all patients will receive the same dose. Guadecitabine and mocetinostat will be given at different doses to fi…
Phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New combo therapy shows promise for relapsed leukemia
Disease control CompletedThis is a Phase I/II study of blinatumomab in combination with pembrolizumab in adult patients with relapsed or refractory B-lineage ALL (B-ALL). The primary objective of this study is to determine if the addition of pembrolizumab to blinatumomab improves the Complete Response Ra…
Phase 1/2 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New drug combo shows promise for Hard-to-Treat breast cancer
Disease control CompletedThis phase II trial studies how well FASN inhibitor TVB-2640, paclitaxel, and trastuzumab work in treating patients with HER2 positive breast cancer that has spread to other places in the body (metastatic). FASN inhibitor TVB-2640 may stop the growth of tumor cells by blocking so…
Phase 2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New scan could spot hidden prostate cancer
Diagnosis OngoingBackground: Prostate cancer is the second leading cause of cancer deaths in American men. When prostate cancer is confined to the prostate there is a high chance of cure. However, it is outside the prostate or comes back after treatment, additional therapy may be needed. Current…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Diagnosis
Last updated Sep 04, 2026 00:00 UTC